<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; secret</title>
	<atom:link href="http://www.tapanray.in/tag/secret/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Big Pharma Demands Transparency, Keeping their &#8216;Black-Boxes&#8217; Tight and Safe?</title>
		<link>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe</link>
		<comments>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/#comments</comments>
		<pubDate>Mon, 28 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revelation]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[samples]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[sponsorship]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tight]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wasteful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2780</guid>
		<description><![CDATA[Pharmaceutical Industry across the globe wants absolute transparency in all government laws, policies, guidelines, transactions and overall governance. They also expect the trade environment should be predictable, non-manipulative and business-friendly. These expectations are indeed well justified and deserve whole-hearted support &#8230; <a href="http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Data Protection and Indian Interest</title>
		<link>http://www.tapanray.in/regulatory-data-protection-and-indian-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-data-protection-and-indian-interest</link>
		<comments>http://www.tapanray.in/regulatory-data-protection-and-indian-interest/#comments</comments>
		<pubDate>Thu, 17 Dec 2009 00:30:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=694</guid>
		<description><![CDATA[Of late, I read and hear raging debates, especially through media, on the relevance of Regulatory Data Protection (RDP) or Data Exclusivity in India. This issue is being considered by many as a fight between the commercial interests of multinational &#8230; <a href="http://www.tapanray.in/regulatory-data-protection-and-indian-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-data-protection-and-indian-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality</title>
		<link>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality</link>
		<comments>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/#comments</comments>
		<pubDate>Tue, 08 Dec 2009 07:13:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[pharmacuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[versus]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=703</guid>
		<description><![CDATA[THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in &#8230; <a href="http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality</title>
		<link>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2</link>
		<comments>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/#comments</comments>
		<pubDate>Mon, 07 Dec 2009 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[pharmacuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[versus]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=706</guid>
		<description><![CDATA[THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in &#8230; <a href="http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
